Letters sent to healthcare professionals in May 2017

Letters were sent about Pharmalgen (Bee Venom and Wasp Venom) Initial kits, bendamustine (Levact), and ERWINASE.

From:
Medicines and Healthcare products Regulatory Agency
Published
21 June 2017
Therapeutic area:
Cancer, Haematology and oncology and Immunology and vaccination

In May 2017, letters were sent about:

  • Pharmalgen (Bee Venom and Wasp Venom) Initial kits: ; risk of dosing errors (see )

  • Bendamustine (Levact): observed when used in non-approved combination treatments or outside approved indications

  • ERWINASE: 鈥攙ials of ERWINASE from batch 182G should be used with a 5-micron filter needle

Article citation: Drug Safety Update volume 10 issue 11, June 2017: 5.

Updates to this page

Published 21 June 2017